Dossier assessment
Brentuximab vedotin (advanced Hodgkin lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Report documents
-
Dossier assessment
Brentuximab vedotin (advanced Hodgkin lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Project details
- Project no.
- G19-09
- Commission
- Commission awarded on 06.03.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Cancer
- Note
-
In accordance with § 35a (para. 1, sentence 11) Social Code Book V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. For the Brentuximab vedotin report commissioned by the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. The resolution on the extent of added benefit is passed by the G-BA after the hearing. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA Website.
Connected Projects
-
Dossier assessment
Brentuximab vedotin (cutaneous T-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Brentuximab vedotin (Hodgkin lymphoma with an increased risk of relapse or progression) - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V
Status: Commission completed
-
Dossier assessment
Brentuximab Vedotin - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Brentuximab vedotin (systemic anaplastic large cell lymphoma, first line) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Brentuximab vedotin (systemic anaplastic large cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)
Status: Commission completed